Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in
addition to routine diagnostic workup (including FDG PET/CT) at primary staging and
restaging.
The FAPI PET/CT results will be compared to conventional imaging (including FDG PET/CT) using
histopathology as reference standard, and the diagnostic accuracy will be determined.
FAP-immunohistochemistry will be conducted in surgical specimens. FAPI PET/CT's impact on
patient management and the prognostic value of FAPI PET/CT will be evaluated.